A key strength of this study is that it leverages one of the largest clinico‐genomic datasets to date of participants with PIK3CAmut ER+, HER2− breast cancer treated with a PI3K inhibitor, allowing for detailed subgroup analyses based on genomic alteration status. This evidence concerns the gene ERBB2 and breast carcinoma.